<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506948</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0435</org_study_id>
    <nct_id>NCT00506948</nct_id>
  </id_info>
  <brief_title>Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)</brief_title>
  <official_title>Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of rabbit
      anti-thymocyte globulin (Thymoglobulin®), sirolimus (Rapamune®), and mycophenolate mofetil
      (Cellcept®) can help to prevent graft versus host disease (GVHD). The safety of this drug
      combination will also be studied.

      Primary Objective: To determine efficacy and toxicity of a regimen of thymoglobulin,
      sirolimus and mycophenolate mofetil for prevention of acute GVHD after allogeneic stem cell
      transplantation from human leukocyte antigen (HLA) identical related or unrelated donors.

      Secondary Objective: To assess engraftment, chronic GVHD, relapse and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rabbit anti-thymocyte globulin (rATG), sirolimus, and mycophenolate mofetil (MMF) are all
      designed to prevent GVHD.

      If you are found to be eligible to take part in this study, you will receive rATG through a
      needle in your vein over 3-4 hours on each of the 4 days before the stem cell transplant.

      Beginning 2 days before the transplant, you will take sirolimus by mouth once per day. You
      will continue to receive sirolimus until 90 days after the transplant. Beginning on Day 60,
      you will start taking increasingly lower doses of the study drug. This is done so you can
      taper down slowly, and be off of the drug on Day 90.

      Beginning on the day of the transplant, you will take MMF by mouth 2 times a day. You will
      continue to take MMF until 27 days after the transplant.

      Every week (for the first 90-100 days after the transplant) you will have study visits. At
      this visit, you will have a physical exam. Blood (about 1-2 tablespoons) will be drawn for
      routine tests.

      You will remain on study for up to 90 days after transplantation. You will be taken off study
      if intolerable side effects occur.

      Starting on Day 90 after the transplant, you will continue to follow up with your transplant
      doctor at least every 3 months through 1 year after the transplant. During these visits you
      will have physical exams. Blood (about 1-2 tablespoons) will be drawn for routine tests. Your
      doctor may request additional testing.

      This is an investigational study. RATG, sirolimus, and MMF are all FDA approved for their use
      in the transplantation of solid organs (like kidney and liver). All 3 drugs are commercially
      available. This particular combination and dose schedule is considered investigational. Up to
      30 patients will take part in this study. All will be enrolled at M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Halted due to high incidence of veno-oclusive disease of the liver.
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure Rate</measure>
    <time_frame>Baseline to 100 days post transplant</time_frame>
    <description>Efficacy failure defined as a participants who had either grade 3-4 acute graft-versus-host disease (aGVHD) or treatment related mortality (TRM) within 100 days post transplant. Failure Rate calculated as (# of failures) / (# participants evaluated). Physical exam and bloodwork every week (for the first 90-100 days after the transplant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acute Graft-versus-host Disease (aGVHD)</measure>
    <time_frame>Baseline to 100 days post transplant</time_frame>
    <description>Participants who had acute graft-versus-host disease (aGVHD) within 100 days post transplant. Physical exam and bloodwork every week (for the first 90-100 days after the transplant).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin + Sirolimus + MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil (MMF)</intervention_name>
    <description>15 mg/kg by vein or by mouth every 12 hours.</description>
    <arm_group_label>Thymoglobulin + Sirolimus + MMF</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>1.5 mg/kg by vein daily for 4 days</description>
    <arm_group_label>Thymoglobulin + Sirolimus + MMF</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>rATG</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.</description>
    <arm_group_label>Thymoglobulin + Sirolimus + MMF</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Thymoglobulin + Sirolimus + MMF</arm_group_label>
    <other_name>hematopoietic stem cell transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with high risk hematological malignancies, including those with induction
             failure and after treated or untreated relapse. High risk hematological malignancies
             include: Acute myelogenous or lymphocytic leukemia with induction failure of after
             relapse, myelodysplastic syndrome of intermediate and high risk according to Greenberg
             criteria, chronic myelogenous leukemia in accelerated phase or blast crisis,
             non-Hodgkin's and Hodgkin's lymphoma with induction failure or relapse after
             chemotherapy and refractory or relapsed chronic lymphocytic leukemia.

          2. HLA-identical sibling or matched unrelated donor transplants not eligible for
             protocols of higher priority.

          3. Age 18-75 years.

          4. Bilirubin &lt;/=1.5 mg/dl, serum glutamic-pyruvic transaminase (SGPT) &lt;/= 200 IU/ml.

          5. Creatinine &lt;/=1.6 mg/dl.

        Exclusion Criteria:

          1. Regimens including rituximab or alemtuzumab in the preparative regimen.

          2. Patients can not have received prior treatment with gemtuzumab.

          3. Planned conditioning chemotherapy for transplant can not include gemtuzumab.

          4. Planned conditioning chemotherapy for transplant can not include the busulfan and
             cyclophosphamide regimen.

          5. HIV seropositivity

          6. Uncontrolled infection, not responding to adequate antimicrobial therapy after 7 days
             of treatment. The protocol PI is the final arbiter of eligibility.

          7. Pregnancy

          8. Inability to sign consent.

          9. Patients who are past recipients of allogeneic or autologous stem cell transplants
             from any source.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Alousi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas (UT) MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>January 7, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2014</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematological Malignancies</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>AHSCT</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>T-Cells</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>rATG</keyword>
  <keyword>Rabbit Antithymocyte Globulin</keyword>
  <keyword>Rapamune</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>Cellcept</keyword>
  <keyword>MMF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 08, 2006 to October 27, 2009. All recruitment done in a medical clinic setting.</recruitment_details>
      <pre_assignment_details>Of the 13 participants enrolled, three participants were ineligible and excluded from the study before treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Thymoglobulin + Sirolimus + MMF</title>
          <description>Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thymoglobulin + Sirolimus + MMF</title>
          <description>Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="26" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Failure Rate</title>
        <description>Efficacy failure defined as a participants who had either grade 3-4 acute graft-versus-host disease (aGVHD) or treatment related mortality (TRM) within 100 days post transplant. Failure Rate calculated as (# of failures) / (# participants evaluated). Physical exam and bloodwork every week (for the first 90-100 days after the transplant).</description>
        <time_frame>Baseline to 100 days post transplant</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Graft-versus-host Disease (aGVHD)</title>
        <description>Participants who had acute graft-versus-host disease (aGVHD) within 100 days post transplant. Physical exam and bloodwork every week (for the first 90-100 days after the transplant).</description>
        <time_frame>Baseline to 100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin + Sirolimus + MMF</title>
            <description>Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Graft-versus-host Disease (aGVHD)</title>
          <description>Participants who had acute graft-versus-host disease (aGVHD) within 100 days post transplant. Physical exam and bloodwork every week (for the first 90-100 days after the transplant).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting from active treatment completed on day 90 (last day of sirolimus) through post-study surveillance to Day +100. Adverse events were collected for a total study period of 2 years and 11 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thymoglobulin + Sirolimus + MMF</title>
          <description>Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Two deaths related to cases of veno-occlusive disease of the liver.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease of the liver</sub_title>
                <description>Two of the four cases were fatal.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GVHD</sub_title>
                <description>Liver, skin (rash), mucosa, and gastrointestinal tract.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Veno-occlusive disease of the liver (Moderate)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A decision to terminate this trial was made due to the high incidence of veno-occlusive disease of the liver in participants receiving this graft-versus-host disease (GVHD) prophylaxis regimen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amin Alousi, MD / Professor</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

